Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Iterum Therapeutics

Iterum Therapeutics?uq=w9if130k
2015 FOUNDED
PUBLIC STATUS
31-40 EMPLOYEES
ITRM STOCK SYMBOL
$8.70 SHARE PRICE (As of Friday Closing)
Description

Developer of significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens. The company's first compound sulopenem, is a novel penem anti-infective compound with oral and IV formulations in an IV only class of antibiotics that has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • Block 2 Floor 3, Harcourt Centre
  • Harcourt Street
  • Dublin 2
  • Ireland

+353 (01) 000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Iterum Therapeutics’s full profile, request a free trial.

Iterum Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$8.30 - $12.85 $119M $8.67 60.4K 14.2M

Iterum Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 28,181
Revenue 508 0
EBITDA (45,011) (29,174) (13,351)
Net Income (45,182) (29,406) (13,464)
Total Assets 145,470 46,757 26,917
Total Debt 14,505 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Iterum Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Iterum Therapeutics‘s full profile, request access.

Request full access to PitchBook

Iterum Therapeutics Executive Team (8)

Name Title Board
Seat
Contact
Info
Corey Fishman Founder, President, Chief Executive Officer & Board Member
Judith Matthews Chief Financial Officer
Michael Dunne MD Chief Scientific Officer
Jeff Schaffnit Chief Commercial Officer
John White Vice President, Business Development & Supply Chain
You’re viewing 5 of 8 executives. Get the full list »

Iterum Therapeutics Board Members (11)

Name Representing Role Since Contact
Info
Corey Fishman Iterum Therapeutics Founder, President, Chief Executive Officer & Board Member 000 0000
David Kelly Iterum Therapeutics Board Member 000 0000
Paul Edick Self Chairman 000 0000

8 Former Board Members

You’re viewing 3 of 11 board members. Get the full list »